Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.06 - $51.86 $260,390 - $337,090
6,500 Added 14.94%
50,000 $2 Million
Q2 2024

Aug 13, 2024

BUY
$36.45 - $47.7 $1.15 Million - $1.5 Million
31,500 Added 262.5%
43,500 $2.07 Million
Q1 2024

May 15, 2024

SELL
$42.03 - $53.55 $756,540 - $963,900
-18,000 Reduced 60.0%
12,000 $520,000
Q4 2023

Feb 13, 2024

BUY
$43.39 - $51.63 $915,529 - $1.09 Million
21,100 Added 237.08%
30,000 $1.52 Million
Q3 2023

May 14, 2024

SELL
$38.5 - $47.13 $812,350 - $994,443
-21,100 Reduced 70.33%
8,900 $403,000
Q3 2023

Nov 14, 2023

BUY
$38.5 - $47.13 $342,650 - $419,457
8,900 New
8,900 $403,000
Q4 2022

May 14, 2024

SELL
$37.12 - $46.52 $185,600 - $232,600
-5,000 Reduced 16.67%
25,000 $944,000
Q4 2022

Feb 13, 2023

BUY
$37.12 - $46.52 $927,999 - $1.16 Million
25,000 New
25,000 $944,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.12B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.